<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41305</article-id><article-id pub-id-type="doi">10.7554/eLife.41305</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-119620"><name><surname>Brien</surname><given-names>Gerard L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120044"><name><surname>Remillard</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80292"><name><surname>Shi</surname><given-names>Junwei</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120045"><name><surname>Hemming</surname><given-names>Matthew L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120046"><name><surname>Chabon</surname><given-names>Jonathon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120047"><name><surname>Wynne</surname><given-names>Kieran</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120048"><name><surname>Dillon</surname><given-names>Eugène T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120049"><name><surname>Cagney</surname><given-names>Gerard</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124407"><name><surname>Van Mierlo</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124406"><name><surname>Baltissen</surname><given-names>Marijke P</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-125315"><name><surname>Vermeulen</surname><given-names>Michiel</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104530"><name><surname>Qi</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120050"><name><surname>Fröhling</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4531"><name><surname>Gray</surname><given-names>Nathanael S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5354-7403</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20510"><name><surname>Bradner</surname><given-names>James E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-23621"><name><surname>Vakoc</surname><given-names>Christopher R</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-119628"><name><surname>Armstrong</surname><given-names>Scott A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9099-4728</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pediatric Oncology</institution>, <institution>Dana Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Dana Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Cancer Biology, Abramson Family Cancer Research Institute</institution>, <institution>University of Pennsylvania</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">School of Biomolecular and Biomedical Science</institution>, <institution>University College Dublin</institution>, <addr-line><named-content content-type="city">Dublin</named-content></addr-line>, <country>Ireland</country></aff><aff id="aff5"><institution content-type="dept">Department of Molecular Biology</institution>, <institution>Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen</institution>, <addr-line><named-content content-type="city">Nijmegen</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff6"><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution>German Cancer Consortium (DKTK)</institution>, <addr-line><named-content content-type="city">Heidelberg</named-content></addr-line>, <country>Germany</country></aff><aff id="aff8"><institution>Cold Spring Harbor Laboratory</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-17592"><name><surname>van Lohuizen</surname><given-names>Maarten</given-names></name><role>Reviewing editor</role><aff><institution>The Netherlands Cancer Institute</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>gbrien@tcd.ie</email> (GB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Scott_armstrong@dfci.harvard.edu</email> (SA);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>11</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e41305</elocation-id><history><date date-type="received"><day>21</day><month>08</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Brien et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Brien et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-41305-v1.pdf"/><abstract><p>Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression <italic>in vivo</italic>. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA176745</award-id><principal-award-recipient><name><surname>Armstrong</surname><given-names>Scott A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001445</institution-id><institution>Alex's Lemonade Stand Foundation for Childhood Cancer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Armstrong</surname><given-names>Scott A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>ALTF-1235-2015</award-id><principal-award-recipient><name><surname>Brien</surname><given-names>Gerard L</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001593</institution-id><institution>Irish Cancer Society</institution></institution-wrap></funding-source><award-id>CRF18BRI</award-id><principal-award-recipient><name><surname>Brien</surname><given-names>Gerard L</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA066996</award-id><principal-award-recipient><name><surname>Armstrong</surname><given-names>Scott A</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA204915</award-id><principal-award-recipient><name><surname>Armstrong</surname><given-names>Scott A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Scott A Armstrong, is a consultant and/or shareholder for Imago Biosciences, Cyteir Therapeutics, C4 Therapeutics, Syros Pharmaceuticals, OxStem Oncology, ProQR and Accent Therapeutics. Also receives research support from Janssen, Novartis, and AstraZeneca..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All mouse experiments were performed according to approved institutional animal care and use committee (IACUC) protocols at the Dana Farber Cancer Institute.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All next-generation sequencing datasets generated in association with this work have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE113229</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Brien GL</collab></person-group><year iso-8601-date="2018">2018</year><source>Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113229">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113229</ext-link><comment>NCBI Gene Expression Omnibus, GSE113229</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-41305-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>